KOAH'DA NİTRİK OKSİT VE TOTAL ANTİOKSİDAN KAPASİTE DÜZEYLERİNİN ÖLÇÜMÜ
Bu çalışmada stabil KOA H hastalarında serumda nitrik oksit (NO) ve total antioksidan kapasite (TAOK) düzeyleri çalışılmıştır. KOAH'lı 47 hasta ile aynı sayıdaki sağlıklı erişkin kontrol grubu olarak çalışmaya alındı. Hasta ve kontrol grubu serumlarında oksidatif stres belirteci olarak nitrik oksit (NO) düzeyleri ile antioksidan savunma sisteminin toplam göstergesi olan total antioksidan kapasite (TAOK) ölçüldü. KOAH hasta grubu 47 kişiydi (27 erkek, 20 kadın) ve yaş ortalaması 66.7±8.3 yıldı. Kontrol grubu da 47 kişiydi (28 erkek, 19 kadın) ve yaş ortalaması 63.2±9.4 yıldı ve iki grup yaş ve cinsiyet açısından arasında fark saptanmadı.
MEASURING THE LEVELS OF NITRIC OXIDE AND TOTAL ANTIOXIDANT CAPACITY IN COPD
In this study were studied level of serum nitric oxide (NO) and total antioxidant capacity (TAS) levels in stable COPD patients. A total of 47 patients with stable COPD and 47 control were included the study. In patients and control group, as a marker of oxidative stress in serum of nitric oxide (NO) levels and total anti-oxidant defense system, which is an indicator of total antioxidant capacity (TAS) were measured. 47 was the group of COPD patients (27 men, 20 women) and mean age 66.7±8.3 years. The control group also was the 47 (28 male, 19 female) and mean age 63.2±9.4 years, and there was no difference between the two groups in terms of age and gender.
___
- 1. Agusti AGN. COPD, multicomponent disease;
implication for management. Respir Med
2005; 99(6): 670-82.
- 2. Türk Toraks Derne¤i Kronik Obstrüktif Akci¤er
Hastal›¤› Tan› ve Tedavi Uzlafl› Raporu. May›s
2010;(11): 16-21.
- 3. Kirkham P, Rahman I. Oxidative stress in asthma
and COPD: antioxidants as a therapeutic
strategy. Pharmacol Ther 2006 111(2): 476-94.
- 4. Sugiura H, Ichinose M. Nitrative stress in
inflammatory lung diseases. Nitric oxide
2011 Apr 2.
- 5. Louhelainen N, Myllarniemi M, Rahman I,
Kinnula VL. Airway biomarkers of the oxidant
burden in asthma and COPD: Current and
future perspectives. Int J Chron Obstruct
Pulmon Dis 2008; 3(4): 585-603.
- 6. Owen CA. Proteinases and Oxidants as Targets
in the treatment of Chronic Obstructive
Pulmonary Disease. Proc Am Thorac Soc 2005;
2: 373-85.
- 7. Rahman I, Morrison D, Donaldson K, MacNee W.
Systemic oxidative stres in asthma, COPD, in
smokers. Am J Respir Crit Care Med 1996;
154: 1055-60.
- 8. Miller NJ, Rice-Evans C, Davies MJ, Gopinathan
V, Milner A. A novel method for measuring
antioxidant capacity and its application to
monitoring the antioxidant status in premature
neonates. Clin Sci 1993; 84(4): 407-12.
- 9. Erel O. A novel automated method to measure
total antioxidant response against potent
free radical reactions. Clin Biochem 2004;
37(2): 112-9.
- 10. http://www.goldcopd.com/Guidelineitem.asp?
l1=2&l2=1&intId=2003 (acces date:01.06.2011).
- 11. Cortas NK, Wakid NW. Determination of
inorganic nitrate in serum and urine by a
kinetic cadmium-reduction method. Clin Chem
1990; 36: 1440-3.
- 12. Rahman I, MacNee W. Oxidant/antioxidant
imbalance in smokers and chronic obstructive
pulmonary disease. Thorax 1996; 51: 348-50.
- 13. Mark JCW. Pathogenesis of COPD. Part 2.
Oxidative-antioxidative imbalance. Int J Tuberc
lung disease 2008; 12(4): 368-74.
- 14. Nadeem A, Raj HG, Chhabra SK. Increased
oxidative stress and altered levels of antioxidants
in chronic obstructive pulmonary
disease. Inflammation 2005; 29(1): 23-32.
- 15. Uygungül D, Çimen B, Günefl G, Ulubafl B.
Akci¤er kanserli hastalarda bronkoskopik
lavaj ve serumda total antioksidan, paroksanaz
ve arylesterase düzeylerinin de¤erlendirilmesi.
32. TÜSAD Ulusal Kongresi 2010
Bildiri Özetleri kitab› Elektronik Poster-031,
S 51.
- 16. Erdem S, Kanat F, Ünlü A. Akut Atak, Stabil
KOAH ve Kor Pulmonale Hastalar›nda ADMA,
Arjinin ve NO Düzeylerinin Belirlenmesi.
Selçuk T›p dergisi 2010; 26(1): 9-13.
- 17. Kersul AL et al. Molecular mechanisms of
inflammation during exacerbations of
chronic obstructive pulmonary disease. Arch
Bronconeumol 2011; 47(4): 176-83.